

Documents on Agenda Item 8 - CV Prof. Dr. Iris Loew-Friedrich

Prof. Dr. Iris Loew-Friedrich, Ratingen
Member of various supervisory boards

Personal data:

Date of birth: 17 November 1960
Place of birth: Offenbach am Main
Nationality: German

Education / Academic Background:

- Medical studies, Goethe University Frankfurt am Main
- Medical license (*Approbation*)
- Doctorate (Dr. med.) at the Max Planck Institute for Biophysics, Frankfurt am Main, awarded the “Prize of the Society of Friends of Paul Ehrlich”
- Venia legendi (habilitation) and adjunct professorship in Internal Medicine, Goethe University Frankfurt am Main

Professional background:

University:

1985 – 1992: Resident physician in the Department of Internal Medicine, University Hospital, Faculty of Medicine, Goethe University, Frankfurt am Main; specialization in immunology, nephrology, and transplant medicine; board certification in internal medicine (physician in internal medicine)

1993 – 2000: Private Lecturer in Internal Medicine

Since 2000: Adjunct Professor of Internal Medicine at the Faculty of Medicine, Goethe University Frankfurt am Main

Industry:

1992 – 1996: Clinical Research Physician, Principal Investigator at Hoechst AG, Hoechst Marion Roussel (HMR), based in Wiesbaden / Frankfurt am Main

1996 – 2000: Vice President, Head of the Global Therapeutic Area Rheumatology/Immunology/Bone Diseases, HMR Global Drug Development Center in Bridgewater, NJ / USA

1998 – 2000: Vice President, Head of Global Clinical Management at HMR / Aventis, in Bridgewater, NJ / USA

2000 – 2001: Vice President, Head of Global Projects, BASF Pharma, Ludwigshafen

2001 – 2007: Head of Global Research and Development, Member of the Management Board at Schwarz Pharma AG, Monheim

2007 – 2008: Senior Vice President, Head of Global Development at UCB S.A., Brussels, Belgium

2008 – 2024: Executive Vice President, Chief Medical Officer, Head of Development, Member of the Management Board, UCB S.A., Brussels, Belgium

Since 2024: Advisor

Membership in domestic Supervisory Boards to be formed by law:

- Chair of the Supervisory Board, Evotec SE, Hamburg (until June 11, 2026)
- Member of the Supervisory Board, Fresenius SE & Co. KGaA, Bad Homburg

Membership in comparable domestic or foreign supervisory bodies of commercial enterprises:

- Member of the Board of Directors, Swedish Orphan Biovitrum AB (SOBI), Stockholm, Sweden
- Member of the Board of Directors, Satellos Bioscience Inc., Toronto, Canada
- Member of the Board of Directors, Financière de Tubize S.A., Brussels, Belgium
- Member of the Board of Directors, Zealand Pharma A/S, Søborg, Denmark

Other significant activities:

- Chair of the Board, Celosia Therapeutics Pty Ltd, Sydney, Australia